Literature DB >> 31753932

Successful venetoclax salvage in the setting of refractory, dialysis-dependent multiple myeloma with t(11;14).

Dawn Swan1,2, Caoimhe Delaney3, Alessandro Natoni2, Michael O'Dwyer3,2, Janusz Krawczyk3,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31753932      PMCID： PMC7049357          DOI： 10.3324/haematol.2019.228338

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  12 in total

1.  A gene expression signature for high-risk multiple myeloma.

Authors:  R Kuiper; A Broyl; Y de Knegt; M H van Vliet; E H van Beers; B van der Holt; L el Jarari; G Mulligan; W Gregory; G Morgan; H Goldschmidt; H M Lokhorst; M van Duin; P Sonneveld
Journal:  Leukemia       Date:  2012-05-08       Impact factor: 11.528

2.  Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P Moreau; J San Miguel; P Sonneveld; M V Mateos; E Zamagni; H Avet-Loiseau; R Hajek; M A Dimopoulos; H Ludwig; H Einsele; S Zweegman; T Facon; M Cavo; E Terpos; H Goldschmidt; M Attal; C Buske
Journal:  Ann Oncol       Date:  2017-07-01       Impact factor: 32.976

3.  Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma.

Authors:  G P Kaufman; M A Gertz; A Dispenzieri; M Q Lacy; F K Buadi; D Dingli; S R Hayman; P Kapoor; J A Lust; S Russell; R S Go; Y L Hwa; R A Kyle; S V Rajkumar; S K Kumar
Journal:  Leukemia       Date:  2015-10-21       Impact factor: 11.528

4.  Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM.

Authors:  Philippe Moreau; Asher Chanan-Khan; Andrew W Roberts; Amit B Agarwal; Thierry Facon; Shaji Kumar; Cyrille Touzeau; Elizabeth A Punnoose; Jaclyn Cordero; Wijith Munasinghe; Jia Jia; Ahmed Hamed Salem; Kevin J Freise; Joel D Leverson; Sari Heitner Enschede; Jeremy A Ross; Paulo C Maciag; Maria Verdugo; Simon J Harrison
Journal:  Blood       Date:  2017-08-28       Impact factor: 22.113

5.  CyBorD-DARA is potent initial induction for MM and enhances ADCP: initial results of the 16-BCNI-001/CTRIAL-IE 16-02 study.

Authors:  M O'Dwyer; R Henderson; S D Naicker; M R Cahill; P Murphy; V Mykytiv; J Quinn; C McEllistrim; J Krawczyk; J Walsh; E Lenihan; T Kenny; A Hernando; G Hirakata; I Parker; E Kinsella; G Gannon; A Natoni; K Lynch; A E Ryan
Journal:  Blood Adv       Date:  2019-06-25

6.  Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.

Authors:  Jonas Paludo; Joseph R Mikhael; Betsy R LaPlant; Alese E Halvorson; Shaji Kumar; Morie A Gertz; Suzanne R Hayman; Francis K Buadi; Angela Dispenzieri; John A Lust; Prashant Kapoor; Nelson Leung; Stephen J Russell; David Dingli; Ronald S Go; Yi Lin; Wilson I Gonsalves; Rafael Fonseca; P Leif Bergsagel; Vivek Roy; Taimur Sher; Asher A Chanan-Khan; Sikander Ailawadhi; A Keith Stewart; Craig B Reeder; Paul G Richardson; S Vincent Rajkumar; Martha Q Lacy
Journal:  Blood       Date:  2017-07-06       Impact factor: 22.113

Review 7.  Reprogramming cell death: BCL2 family inhibition in hematological malignancies.

Authors:  Lydia Scarfò; Paolo Ghia
Journal:  Immunol Lett       Date:  2013-10-01       Impact factor: 3.685

8.  Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

Authors:  Elizabeth A Punnoose; Joel D Leverson; Franklin Peale; Erwin R Boghaert; Lisa D Belmont; Nguyen Tan; Amy Young; Michael Mitten; Ellen Ingalla; Walter C Darbonne; Anatol Oleksijew; Paul Tapang; Peng Yue; Jason Oeh; Leslie Lee; Sophie Maiga; Wayne J Fairbrother; Martine Amiot; Andrew J Souers; Deepak Sampath
Journal:  Mol Cancer Ther       Date:  2016-03-03       Impact factor: 6.261

9.  Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma.

Authors:  Shaji Kumar; Jonathan L Kaufman; Cristina Gasparetto; Joseph Mikhael; Ravi Vij; Brigitte Pegourie; Lofti Benboubker; Thierry Facon; Martine Amiot; Philippe Moreau; Elizabeth A Punnoose; Stefanie Alzate; Martin Dunbar; Tu Xu; Suresh K Agarwal; Sari Heitner Enschede; Joel D Leverson; Jeremy A Ross; Paulo C Maciag; Maria Verdugo; Cyrille Touzeau
Journal:  Blood       Date:  2017-10-10       Impact factor: 22.113

10.  The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma.

Authors:  C Touzeau; C Dousset; S Le Gouill; D Sampath; J D Leverson; A J Souers; S Maïga; M C Béné; P Moreau; C Pellat-Deceunynck; M Amiot
Journal:  Leukemia       Date:  2013-07-17       Impact factor: 11.528
View more
  3 in total

1.  Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.

Authors:  Virág Réka Szita; Gábor Mikala; András Kozma; János Fábián; Apor Hardi; Hussain Alizadeh; Péter Rajnics; László Rejtő; Tamás Szendrei; László Váróczy; Zsolt Nagy; Árpád Illés; István Vályi-Nagy; Tamás Masszi; Gergely Varga
Journal:  Pathol Oncol Res       Date:  2022-02-28       Impact factor: 3.201

2.  Successful treatment of relapsed chronic lymphocytic leukemia with venetoclax in a patient with severe chronic kidney disease.

Authors:  Hiroyuki Sugiura; Nobuo Sezaki; Tatsunori Ishikawa; Taiga Kuroi; Sachiyo Okamoto; Naho Nomura; Taro Masunari; Yukio Nakasako; Toru Kiguchi; Mitsune Tanimoto
Journal:  Clin Case Rep       Date:  2022-04-14

3.  Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.

Authors:  Carolane Seiller; Sophie Maiga; Cyrille Touzeau; Céline Bellanger; Charlotte Kervoëlen; Géraldine Descamps; Laurent Maillet; Philippe Moreau; Catherine Pellat-Deceunynck; Patricia Gomez-Bougie; Martine Amiot
Journal:  Cell Death Dis       Date:  2020-05-05       Impact factor: 8.469
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.